Figure 1. A 57-year-old female patient with a metastatic neuroendocrine tumor who was treated for L3 vertebral metastasis to a dose of 16 Gy in a single session, prescribed to a 71% isodose line.
Approximately 6 months after treatment, the patient returned for follow-up and was found to have an asymptomatic vertebral body fracture at the site of original treatment. (A) The delivered treatment. (B & D) T2-weighted magnetic resonance sequences at 3 and 6 months, respectively, and (C & E) T1-weighted sequences at 3 and 6 months, respectively. (D & E) Loss of L3 vertebral body height at 6 months.